Market capitalization | $5.41m |
Enterprise Value | $3.04m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 2.14 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-8.71m |
Free Cash Flow (TTM) Free Cash Flow | $-6.88m |
Cash position | $2.37m |
As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.
2 Analysts have issued a Adial Pharmaceuticals, Inc. forecast:
2 Analysts have issued a Adial Pharmaceuticals, Inc. forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -8.71 -8.71 |
35%
35%
|
EBIT (Operating Income) EBIT | -8.71 -8.71 |
35%
35%
|
Net Profit | -8.95 -8.95 |
3%
3%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.
Head office | United States |
CEO | Cary Claiborne |
Employees | 5 |
Founded | 2010 |
Website | www.adialpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.